Soumettre la recherche
Mettre en ligne
Negotiating the Deal
•
1 j'aime
•
1,171 vues
Lindsay Meyer
Suivre
Slides from October 2010 presentation at QB3's Global Bio-Entrepreneurship Course
Lire moins
Lire la suite
Économie & finance
Business
Signaler
Partager
Signaler
Partager
1 sur 40
Télécharger maintenant
Télécharger pour lire hors ligne
Recommandé
How to Raise Seed Funding for Your Startup: Convertible Notes and SAFEs
How to Raise Seed Funding for Your Startup: Convertible Notes and SAFEs
ideatoipo
Antecedentes del problema de la proteccion del software
Antecedentes del problema de la proteccion del software
Daniel Fuentes Nava
Comenzar
Comenzar
dmateran02
Blueprint Builders lends a Helping Hand by John Barlow
Blueprint Builders lends a Helping Hand by John Barlow
John R. Barlow Minneapolis
May 2013 EHR Market Share
May 2013 EHR Market Share
Lindsay Meyer
Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking...
Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking...
BioWorld Today, Now a Part of Thomson Reuters
Market Study of Electronic Medical Record (EMR) Systems in Europe
Market Study of Electronic Medical Record (EMR) Systems in Europe
CGI
Life Sciences Licensing — Trends and Issues
Life Sciences Licensing — Trends and Issues
This account is closed
Recommandé
How to Raise Seed Funding for Your Startup: Convertible Notes and SAFEs
How to Raise Seed Funding for Your Startup: Convertible Notes and SAFEs
ideatoipo
Antecedentes del problema de la proteccion del software
Antecedentes del problema de la proteccion del software
Daniel Fuentes Nava
Comenzar
Comenzar
dmateran02
Blueprint Builders lends a Helping Hand by John Barlow
Blueprint Builders lends a Helping Hand by John Barlow
John R. Barlow Minneapolis
May 2013 EHR Market Share
May 2013 EHR Market Share
Lindsay Meyer
Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking...
Biopharmaceutical Royalty Rates Analysis: Essential Benchmarks for Dealmaking...
BioWorld Today, Now a Part of Thomson Reuters
Market Study of Electronic Medical Record (EMR) Systems in Europe
Market Study of Electronic Medical Record (EMR) Systems in Europe
CGI
Life Sciences Licensing — Trends and Issues
Life Sciences Licensing — Trends and Issues
This account is closed
Iact sbir overview from bbc 4 27-2021
Iact sbir overview from bbc 4 27-2021
douglaslyon
Driss temsamani Big Data Marketing Innovation Summit 2015 Keynote
Driss temsamani Big Data Marketing Innovation Summit 2015 Keynote
Driss R. Temsamani
Driss temsamani big data marketing innovation summit 2015
Driss temsamani big data marketing innovation summit 2015
Driss R. Temsamani
Govt. trad. and non trad. contracting for sme
Govt. trad. and non trad. contracting for sme
Alan1001001
Aagami Corporate Presentation March 2024
Aagami Corporate Presentation March 2024
Aagami, Inc.
The Thawing of the Credit Markets
The Thawing of the Credit Markets
Franz von Bradsky
Robo-Advisors: Industry Changers or Also-Rans?
Robo-Advisors: Industry Changers or Also-Rans?
Deloitte United States
Pharm Collaborations Cbi Pres
Pharm Collaborations Cbi Pres
thess1121
MGMT 530 Inspiring Innovation / tutorialrank.com
MGMT 530 Inspiring Innovation / tutorialrank.com
Bromleyz2
MGMT 530 Education Specialist / snaptutorial.com
MGMT 530 Education Specialist / snaptutorial.com
stevesonz150
Deloitte US Comments on Cost Contribution Arrangements Discussion Draft
Deloitte US Comments on Cost Contribution Arrangements Discussion Draft
Philippe Penelle
Wake Up and Smell the New M&A Imperative_ May 2019 FBA CFO Symposium
Wake Up and Smell the New M&A Imperative_ May 2019 FBA CFO Symposium
Mona Ashour
Pa Bio 10 29 08
Pa Bio 10 29 08
thess1121
Hedge accounting: Simplifying the accounting for hedging activities
Hedge accounting: Simplifying the accounting for hedging activities
Deloitte United States
Elements of Shovel Ready Projects for Stimulus Funding
Elements of Shovel Ready Projects for Stimulus Funding
jslaney
disruption-claims-forum-presentation.pptx
disruption-claims-forum-presentation.pptx
Rizwan695555
MGMT 530 Enhance teaching - snaptutorial.com
MGMT 530 Enhance teaching - snaptutorial.com
DavisMurphyA84
The exit dave litwiller - jan 31 2012
The exit dave litwiller - jan 31 2012
Dave Litwiller
Breakout Session: Head for the Exit: How to Structure, Negotiate & Close the ...
Breakout Session: Head for the Exit: How to Structure, Negotiate & Close the ...
Healthegy
HIDA - Expo & Business Exchange: Working With the Federal Government
HIDA - Expo & Business Exchange: Working With the Federal Government
JSchaus & Associates
Dummy Cap Table & Returns Analysis - Round B
Dummy Cap Table & Returns Analysis - Round B
Lindsay Meyer
2013 HealthTech Conference Notes
2013 HealthTech Conference Notes
Lindsay Meyer
Contenu connexe
Similaire à Negotiating the Deal
Iact sbir overview from bbc 4 27-2021
Iact sbir overview from bbc 4 27-2021
douglaslyon
Driss temsamani Big Data Marketing Innovation Summit 2015 Keynote
Driss temsamani Big Data Marketing Innovation Summit 2015 Keynote
Driss R. Temsamani
Driss temsamani big data marketing innovation summit 2015
Driss temsamani big data marketing innovation summit 2015
Driss R. Temsamani
Govt. trad. and non trad. contracting for sme
Govt. trad. and non trad. contracting for sme
Alan1001001
Aagami Corporate Presentation March 2024
Aagami Corporate Presentation March 2024
Aagami, Inc.
The Thawing of the Credit Markets
The Thawing of the Credit Markets
Franz von Bradsky
Robo-Advisors: Industry Changers or Also-Rans?
Robo-Advisors: Industry Changers or Also-Rans?
Deloitte United States
Pharm Collaborations Cbi Pres
Pharm Collaborations Cbi Pres
thess1121
MGMT 530 Inspiring Innovation / tutorialrank.com
MGMT 530 Inspiring Innovation / tutorialrank.com
Bromleyz2
MGMT 530 Education Specialist / snaptutorial.com
MGMT 530 Education Specialist / snaptutorial.com
stevesonz150
Deloitte US Comments on Cost Contribution Arrangements Discussion Draft
Deloitte US Comments on Cost Contribution Arrangements Discussion Draft
Philippe Penelle
Wake Up and Smell the New M&A Imperative_ May 2019 FBA CFO Symposium
Wake Up and Smell the New M&A Imperative_ May 2019 FBA CFO Symposium
Mona Ashour
Pa Bio 10 29 08
Pa Bio 10 29 08
thess1121
Hedge accounting: Simplifying the accounting for hedging activities
Hedge accounting: Simplifying the accounting for hedging activities
Deloitte United States
Elements of Shovel Ready Projects for Stimulus Funding
Elements of Shovel Ready Projects for Stimulus Funding
jslaney
disruption-claims-forum-presentation.pptx
disruption-claims-forum-presentation.pptx
Rizwan695555
MGMT 530 Enhance teaching - snaptutorial.com
MGMT 530 Enhance teaching - snaptutorial.com
DavisMurphyA84
The exit dave litwiller - jan 31 2012
The exit dave litwiller - jan 31 2012
Dave Litwiller
Breakout Session: Head for the Exit: How to Structure, Negotiate & Close the ...
Breakout Session: Head for the Exit: How to Structure, Negotiate & Close the ...
Healthegy
HIDA - Expo & Business Exchange: Working With the Federal Government
HIDA - Expo & Business Exchange: Working With the Federal Government
JSchaus & Associates
Similaire à Negotiating the Deal
(20)
Iact sbir overview from bbc 4 27-2021
Iact sbir overview from bbc 4 27-2021
Driss temsamani Big Data Marketing Innovation Summit 2015 Keynote
Driss temsamani Big Data Marketing Innovation Summit 2015 Keynote
Driss temsamani big data marketing innovation summit 2015
Driss temsamani big data marketing innovation summit 2015
Govt. trad. and non trad. contracting for sme
Govt. trad. and non trad. contracting for sme
Aagami Corporate Presentation March 2024
Aagami Corporate Presentation March 2024
The Thawing of the Credit Markets
The Thawing of the Credit Markets
Robo-Advisors: Industry Changers or Also-Rans?
Robo-Advisors: Industry Changers or Also-Rans?
Pharm Collaborations Cbi Pres
Pharm Collaborations Cbi Pres
MGMT 530 Inspiring Innovation / tutorialrank.com
MGMT 530 Inspiring Innovation / tutorialrank.com
MGMT 530 Education Specialist / snaptutorial.com
MGMT 530 Education Specialist / snaptutorial.com
Deloitte US Comments on Cost Contribution Arrangements Discussion Draft
Deloitte US Comments on Cost Contribution Arrangements Discussion Draft
Wake Up and Smell the New M&A Imperative_ May 2019 FBA CFO Symposium
Wake Up and Smell the New M&A Imperative_ May 2019 FBA CFO Symposium
Pa Bio 10 29 08
Pa Bio 10 29 08
Hedge accounting: Simplifying the accounting for hedging activities
Hedge accounting: Simplifying the accounting for hedging activities
Elements of Shovel Ready Projects for Stimulus Funding
Elements of Shovel Ready Projects for Stimulus Funding
disruption-claims-forum-presentation.pptx
disruption-claims-forum-presentation.pptx
MGMT 530 Enhance teaching - snaptutorial.com
MGMT 530 Enhance teaching - snaptutorial.com
The exit dave litwiller - jan 31 2012
The exit dave litwiller - jan 31 2012
Breakout Session: Head for the Exit: How to Structure, Negotiate & Close the ...
Breakout Session: Head for the Exit: How to Structure, Negotiate & Close the ...
HIDA - Expo & Business Exchange: Working With the Federal Government
HIDA - Expo & Business Exchange: Working With the Federal Government
Plus de Lindsay Meyer
Dummy Cap Table & Returns Analysis - Round B
Dummy Cap Table & Returns Analysis - Round B
Lindsay Meyer
2013 HealthTech Conference Notes
2013 HealthTech Conference Notes
Lindsay Meyer
The #1 Ball in Golf
The #1 Ball in Golf
Lindsay Meyer
Collision Forces: Scientific Integrity Meets the Capital Markets
Collision Forces: Scientific Integrity Meets the Capital Markets
Lindsay Meyer
The Status of the Regulatory and Economic Landscape for Innovation in Big Pha...
The Status of the Regulatory and Economic Landscape for Innovation in Big Pha...
Lindsay Meyer
Three-dimensional Ultrasound: Techniques and Applications in Obstetrics
Three-dimensional Ultrasound: Techniques and Applications in Obstetrics
Lindsay Meyer
The Science of What's In the Bottle: Factors Which Influence pH of White Wine
The Science of What's In the Bottle: Factors Which Influence pH of White Wine
Lindsay Meyer
“Reduction of an Aldehyde or Ketone”
“Reduction of an Aldehyde or Ketone”
Lindsay Meyer
The Science of What’s in the Bottle: Factors Which Influence pH of White Wine
The Science of What’s in the Bottle: Factors Which Influence pH of White Wine
Lindsay Meyer
$ANF Tear Sheet
$ANF Tear Sheet
Lindsay Meyer
$ANF Valuation Model
$ANF Valuation Model
Lindsay Meyer
Death prompts a review of gene therapy vector
Death prompts a review of gene therapy vector
Lindsay Meyer
Prenatal exposure to isotretinoin
Prenatal exposure to isotretinoin
Lindsay Meyer
Rock Health Demo Day June 2012
Rock Health Demo Day June 2012
Lindsay Meyer
Rock Health Demo Day Notes
Rock Health Demo Day Notes
Lindsay Meyer
BoxWorks SuperSession: “The Future of Healthcare and the Cloud”
BoxWorks SuperSession: “The Future of Healthcare and the Cloud”
Lindsay Meyer
Predictive Analytics in Venture Investing
Predictive Analytics in Venture Investing
Lindsay Meyer
Plus de Lindsay Meyer
(17)
Dummy Cap Table & Returns Analysis - Round B
Dummy Cap Table & Returns Analysis - Round B
2013 HealthTech Conference Notes
2013 HealthTech Conference Notes
The #1 Ball in Golf
The #1 Ball in Golf
Collision Forces: Scientific Integrity Meets the Capital Markets
Collision Forces: Scientific Integrity Meets the Capital Markets
The Status of the Regulatory and Economic Landscape for Innovation in Big Pha...
The Status of the Regulatory and Economic Landscape for Innovation in Big Pha...
Three-dimensional Ultrasound: Techniques and Applications in Obstetrics
Three-dimensional Ultrasound: Techniques and Applications in Obstetrics
The Science of What's In the Bottle: Factors Which Influence pH of White Wine
The Science of What's In the Bottle: Factors Which Influence pH of White Wine
“Reduction of an Aldehyde or Ketone”
“Reduction of an Aldehyde or Ketone”
The Science of What’s in the Bottle: Factors Which Influence pH of White Wine
The Science of What’s in the Bottle: Factors Which Influence pH of White Wine
$ANF Tear Sheet
$ANF Tear Sheet
$ANF Valuation Model
$ANF Valuation Model
Death prompts a review of gene therapy vector
Death prompts a review of gene therapy vector
Prenatal exposure to isotretinoin
Prenatal exposure to isotretinoin
Rock Health Demo Day June 2012
Rock Health Demo Day June 2012
Rock Health Demo Day Notes
Rock Health Demo Day Notes
BoxWorks SuperSession: “The Future of Healthcare and the Cloud”
BoxWorks SuperSession: “The Future of Healthcare and the Cloud”
Predictive Analytics in Venture Investing
Predictive Analytics in Venture Investing
Dernier
VIP Kolkata Call Girl Jodhpur Park 👉 8250192130 Available With Room
VIP Kolkata Call Girl Jodhpur Park 👉 8250192130 Available With Room
divyansh0kumar0
Andheri Call Girls In 9825968104 Mumbai Hot Models
Andheri Call Girls In 9825968104 Mumbai Hot Models
hematsharma006
Instant Issue Debit Cards - School Designs
Instant Issue Debit Cards - School Designs
egoetzinger
Veritas Interim Report 1 January–31 March 2024
Veritas Interim Report 1 January–31 March 2024
Veritas Eläkevakuutus - Veritas Pensionsförsäkring
20240417-Calibre-April-2024-Investor-Presentation.pdf
20240417-Calibre-April-2024-Investor-Presentation.pdf
Adnet Communications
Dividend Policy and Dividend Decision Theories.pptx
Dividend Policy and Dividend Decision Theories.pptx
anshikagoel52
(DIYA) Bhumkar Chowk Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
(DIYA) Bhumkar Chowk Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
ranjana rawat
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
FinTech Belgium
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
shivangimorya083
OAT_RI_Ep19 WeighingTheRisks_Apr24_TheYellowMetal.pptx
OAT_RI_Ep19 WeighingTheRisks_Apr24_TheYellowMetal.pptx
hiddenlevers
Commercial Bank Economic Capsule - April 2024
Commercial Bank Economic Capsule - April 2024
Commercial Bank of Ceylon PLC
(ANIKA) Budhwar Peth Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
(ANIKA) Budhwar Peth Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
ranjana rawat
The Economic History of the U.S. Lecture 22.pdf
The Economic History of the U.S. Lecture 22.pdf
Gale Pooley
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
FinTech Belgium
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
ssifa0344
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
Suhani Kapoor
VIP Kolkata Call Girl Serampore 👉 8250192130 Available With Room
VIP Kolkata Call Girl Serampore 👉 8250192130 Available With Room
divyansh0kumar0
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
Call Girls in Nagpur High Profile
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
Call Girls in Nagpur High Profile
Dharavi Russian callg Girls, { 09892124323 } || Call Girl In Mumbai ...
Dharavi Russian callg Girls, { 09892124323 } || Call Girl In Mumbai ...
Pooja Nehwal
Dernier
(20)
VIP Kolkata Call Girl Jodhpur Park 👉 8250192130 Available With Room
VIP Kolkata Call Girl Jodhpur Park 👉 8250192130 Available With Room
Andheri Call Girls In 9825968104 Mumbai Hot Models
Andheri Call Girls In 9825968104 Mumbai Hot Models
Instant Issue Debit Cards - School Designs
Instant Issue Debit Cards - School Designs
Veritas Interim Report 1 January–31 March 2024
Veritas Interim Report 1 January–31 March 2024
20240417-Calibre-April-2024-Investor-Presentation.pdf
20240417-Calibre-April-2024-Investor-Presentation.pdf
Dividend Policy and Dividend Decision Theories.pptx
Dividend Policy and Dividend Decision Theories.pptx
(DIYA) Bhumkar Chowk Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
(DIYA) Bhumkar Chowk Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
Russian Call Girls In Gtb Nagar (Delhi) 9711199012 💋✔💕😘 Naughty Call Girls Se...
OAT_RI_Ep19 WeighingTheRisks_Apr24_TheYellowMetal.pptx
OAT_RI_Ep19 WeighingTheRisks_Apr24_TheYellowMetal.pptx
Commercial Bank Economic Capsule - April 2024
Commercial Bank Economic Capsule - April 2024
(ANIKA) Budhwar Peth Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
(ANIKA) Budhwar Peth Call Girls Just Call 7001035870 [ Cash on Delivery ] Pun...
The Economic History of the U.S. Lecture 22.pdf
The Economic History of the U.S. Lecture 22.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
06_Joeri Van Speybroek_Dell_MeetupDora&Cybersecurity.pdf
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Call Girls Service Dilsukhnagar Hyderabad Call +91-8250192130
VIP Kolkata Call Girl Serampore 👉 8250192130 Available With Room
VIP Kolkata Call Girl Serampore 👉 8250192130 Available With Room
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
High Class Call Girls Nashik Maya 7001305949 Independent Escort Service Nashik
Dharavi Russian callg Girls, { 09892124323 } || Call Girl In Mumbai ...
Dharavi Russian callg Girls, { 09892124323 } || Call Girl In Mumbai ...
Negotiating the Deal
1.
Negotiating the Deal: Tactics
for Execution QB3 Global Bio-Entrepreneurship Course Lindsay Meyer (limeyer@deloitte.com) Deloitte Recap LLC October 7, 2010
2.
What’s on Tap §
The art of doing deals § Different strokes for different folks § Now it’s your turn § Things you might be interested in knowing § Going to the drawing board § A final word on value creation § Beer Copyright © 2010 Deloitte Recap LLC. All rights reserved. 1
3.
The art of
doing deals
4.
Case #1 –
SEATTLE GENETICS Founded 1998 (Bothell, WA) Cancer & Autoimmune 325 Employees $325M Cash THE ASSET Brentuximab Vedotin, an antibody-drug conjugate targeted to CD30 for Hodgkin and T-cell lymphomas Copyright © 2010 Deloitte Recap LLC. All rights reserved. 3
5.
Why Partner? Pros • Enables
broader global development plan • Supplements resources for: ‒ Late-stage clinical trials ‒ Manufacturing Cons • Could have less control over development, regulatory and commercial decision-making in ROW • Supporting the collaboration might distract internal teams from other proprietary programs ‒ Commercialization • Increases focus on building US/Canada sales & marketing infrastructure • Might delay SGEN’s global commercial expansion • Generates near-term cash flow and longer-term milestones and royalties • Relinquishes some long-term value potential • Non-dilutive financing alternative • Could reduce M&A possibilities • Likely to provide validation and reduces future cost of capital • Termination of the collaboration can taint program • May increase brentuximab’s overall chance of success Copyright © 2010 Deloitte Recap LLC. All rights reserved. 4
6.
Partnering Process § Initial
Contact 35 § Confidential Discussions 20 § Due Diligence § Term Sheets Copyright © 2010 Deloitte Recap LLC. All rights reserved. 10 5 5
7.
Deal Announcement Copyright ©
2010 Deloitte Recap LLC. All rights reserved. 6
8.
Deal Structure Seattle Genetics Novel,
first-in-class therapeutic Strong phase I data Pivotal trial fully enrolled Retains full US and Canadian commercial rights Copyright © 2010 Deloitte Recap LLC. All rights reserved. Millennium to provide: $60M upfront >$230M in milestones Pays 50% of joint development costs Tiered double-digit royalties on ROW sales Deal reduces future financing needs and enables further investment in SGEN pipeline Millennium Global commercial infrastructure Flagship product Velcade Strong oncology expertise Obtains ROW commercial rights 7
9.
Partnering Timeline ~1 mo. ~5
months ~18 months Jan - Dec Due diligence May Partnering process begins July 1st contact with MLNM January Partnering discussions at JPMorgan June 22 1st term sheet with MLNM 2008 June Preliminary partnering meetings at ASCO Nov 9 First draft of definitive agreement with MLNM Dec 16 MLNM deal signed 2009 Nov – Dec Partnering discussions at Bio-Europe and ASH Copyright © 2010 Deloitte Recap LLC. All rights reserved. April 6 ADC deal with MLNM May – June Partnering meetings at ASCO Dec 4 BOD approves MLNM deal 8
10.
Different strokes for different
folks
11.
Case #2 -
AMYLIN Founded 1987 (San Diego, CA) Diabetes & Obesity 1500 Employees $574M Cash THE ASSET A Basket of Obesity Drugs including: Pramlinitide/Metreleptin (Ph. II), Davalintide (Ph. II), AC163954 (OPT), Pre-clinical compound from Takeda Copyright © 2010 Deloitte Recap LLC. All rights reserved. 10
12.
Partnering Considerations Challenge • Roles
and Responsibilities • Competition Against the Collaboration Solution • Divide responsibilities according to each party’s strengths • Employ non-compete provisions which encourage collaboration, but don’t limit scientific research Examples • Amylin controls activities through Phase 2 in the US; Takeda from then on and ex-US • Takeda controls global commercialization • Required nomination of certain additional analogs • Process to propose additional activities, free pursuit if rejected • Changing Regulatory Environments • Define cost sharing for known circumstances and a contingency plan for unknown occurances • 80/20 cost sharing in the US • Decision Making Authority • Create an environment where mutual agreement is the norm • Committees with separate decision making authority • Amylin shares additional costs for certain clinical safety studies • Division of “final say” authority • Defined escalation process Copyright © 2010 Deloitte Recap LLC. All rights reserved. 11
13.
Deal Announcement Copyright ©
2010 Deloitte Recap LLC. All rights reserved. 12
14.
Deal Structure Amylin 3 Phase
2 compounds for obesity Option to license additional compounds Co-promotion option of 1st 2 products Takeda to provide: $75M upfront >$1B in milestones Pays 80% of US development costs Pays 100% of ex-US development costs Tiered double-digit royalties on total annual net sales Takeda Global commercial infrastructure Strong diabetes sales expertise Flagship product Actos Obtains WW commercial rights Loan for CV safety study Copyright © 2010 Deloitte Recap LLC. All rights reserved. 13
15.
Now it’s your
turn
16.
Valuing a Deal Discounted
Cash Flow Copyright © 2010 Deloitte Recap LLC. All rights reserved. Comparables Analysis 15
17.
Transaction Execution Week 1-2 Week
3 Week 4-6 Week 6-18 Week 24 Week 25 • Timing • Process • Contacts • Term Sheets • Key Provisions • Committees • Structure • Targets • Meetings • Competing Bids • Contracts • Managers • Strategy • Sales Deck • Follow-ups • Optimization • Diligence • Optimization • Valuation When should we How should we partner? structure? • Gap Analysis • Target Pools • R&D Diligence • Structure Options • Market Analysis • Valuation • Legal Diligence • Tax Impact Who should we target? • Position with partner’s deal negotiator • Manage expectations How do we How do we avoid maximize value? pitfalls? • Process/Timeline • Term Sheets How do we optimize? • Due Diligence Process/Timeline • Alliance Management • Key Contract Provisions • Deal Optimization and Revision • Generate leads Copyright © 2010 Deloitte Recap LLC. All rights reserved. 16
18.
Structuring and Negotiations §
Consider role of asset in corporate development § Seek forward integration, company valuation, investor liquidity § Have the buyer submit terms, first § Use rational comparables § Get multiple bidders involved § Know minimum requirements Copyright © 2010 Deloitte Recap LLC. All rights reserved. 17
19.
Things you might
be interested in knowing
20.
Partners of Biotech
Programs 70 Pharma Company Licensing and M&A Activity (2009) Number of Deals 60 50 Corp In-Lic Univ In-Lic Out-Lic M&A 40 30 20 10 0 Copyright © 2010 Deloitte Recap LLC. All rights reserved. Source: Deloitte Recap LLC 19
21.
Therapeutic Focus 800 Number of
Deals by Stage at Signing and Field (2005 – 2010) 700 600 500 400 300 Disc/Lead Preclinical Phase I Phase II Phase III+ 200 100 0 Copyright © 2010 Deloitte Recap LLC. All rights reserved. 20
22.
Early Stage Payment
Trends Over Time 1990 1995 2000 2005 2010 Upfront $0.1 $1 $1 $2 $9 R&D $0.9 $7 $5 $7 $9 Milestones $0.2 $5 $7 $33 $124 Royalty 5% 6% 8% 35% Total Size $0.2 $6 $9 $33 Licensing data from Recap IQ by Deloitte 2010 data through September; no royalty figures available Copyright © 2010 Deloitte Recap LLC. All rights reserved. $138 21
23.
Going to the
drawing board
24.
Commercialization Contracts Research &
Development Product License • License / Sublicense • Royalty • License Maintenance Manufacturing & Supply • Manufacturing & Supply Rights • Reimbursement • Escape / Liability Alliance Management • Implementation & Management Equity Investment Copyright © 2010 Deloitte Recap LLC. All rights reserved. • Field & Scope • Consideration Payable • IP & Regulatory • Control • Equity Investment Types & Pricing 23
25.
Contractual Basics § Field
and scope § Governance § Territory and major markets § IP and regulatory § Supply and manufacturing rights § Financial and audit provisions § Term and termination Copyright © 2010 Deloitte Recap LLC. All rights reserved. 24
26.
Must Have § Duration
of research § Sublicense rights § Patent defense responsibilities § 3rd party infringement responsibilities § Net sales definition § Reimbursement basis for commercial supply § Reversion rights § Dispute escalation Copyright © 2010 Deloitte Recap LLC. All rights reserved. 25
27.
Must Have Examples:
Amylin 15.1 Objective. The Parties recognize that disputes as to matters arising under or relating to this Agreement or either Party’s rights and/or obligations hereunder may arise from time to time. It is the objective of the Parties to establish procedures to facilitate the resolution of such disputes in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 15 to resolve any such dispute if and when it arises. […] such dispute shall be subject to the dispute resolution provisions contained in Sections 15.2 and 15.3. 15.2 Resolution by Senior Executives. Except as otherwise provided in this Agreement including Section 15.1, if an unresolved dispute as to matters arising under or relating to this Agreement or either Party’s rights and/or obligations hereunder arises, either Party may refer such dispute to the Chief Executive Officers of each of Takeda and Amylin (or such delegate of either Chief Executive Officer who shall have appropriate decision making authority regarding such dispute) […]. If such matter cannot be resolved by discussion of Chief Executive Officers […] such dispute shall be resolved in accordance with Section 15.3. 15.3 Arbitration. Any dispute that is not resolved as provided in Section 15.2 may be referred to arbitration by either Party. Such arbitration shall be conducted in accordance with the Rules of Arbitration of the International Chamber of Commerce (the “ICC Rules”) as then in effect. The arbitration shall be held solely in New York, New York, U.S.A, and shall be conducted in English […]. Copyright © 2010 Deloitte Recap LLC. All rights reserved. 26
28.
Escalation Process Deciphered §
Obesity Steering Committee attempts to resolve, first § CEO referral follows § Arbitration if no resolution in CON days § Arbitration expenses shared equally by parties Copyright © 2010 Deloitte Recap LLC. All rights reserved. 27
29.
Good to Have §
Defined research terms § Non-compete provision § Due diligence § Publication delays for patent prosecution § Manufacturing escape clauses § Post-term sales rights § Royalty adjustments (and limits) Copyright © 2010 Deloitte Recap LLC. All rights reserved. 28
30.
Good to Have
Examples: Seattle Genetics 5.3 MPI’s Performance. MPI shall use Commercially Reasonable Efforts to prepare and submit the appropriate Regulatory Materials for Licensed Products in the Licensed Territory, as determined on a country-by-country basis, and to seek to obtain Regulatory Approvals (and, if applicable, Pricing Approvals) for Licensed Products in the Licensed Territory, as determined on a country-by-country basis. [***]: (a) [***], and thereafter use Commercially Reasonable Efforts to [***] unless (i) [***] or (ii) [***] (a),[***]; (b) [***]; (c) [***] and [***]; and (d) [***]. […] 12.4 Publications. The JDC shall prepare and approve [***] with respect to the Licensed Product and results of studies carried out under this Agreement. Neither Party may publish manuscripts or give other forms of public disclosure such as abstracts and presentations, of results of studies carried out under this Agreement, without the opportunity for prior review by the other Party or [***]. […]. In addition, the Party seeking publication shall delay the submission for a period up to [***] in the event that the other Party can demonstrate reasonable need for such delay, including without limitation, the preparation and filing of a patent application. Copyright © 2010 Deloitte Recap LLC. All rights reserved. 29
31.
A Variety of
Good Provisions § Well defined diligence requirements (4 tiers, CON) § Deferral of publications for up to CON days to protect IP § Royalty adjustments § Alternate supply may be established at each party’s own expense Copyright © 2010 Deloitte Recap LLC. All rights reserved. 30
32.
Icing on the
Cake § Possible extensions to research period § Right of first refusal to other research § Territory options for inclusion/exclusion § Co-promotion rights (if it makes sense) § Options to repurchase product Copyright © 2010 Deloitte Recap LLC. All rights reserved. 31
33.
Icing Example: Amylin 5.1
Commercialization Activities. Takeda shall be responsible for Commercializing Products in the Field in the Territory, including conducting any Post-Approval Clinical Studies, at its own expense, subject to the terms and conditions of this Agreement and in compliance in all material respects with Applicable Laws. Takeda shall be responsible for all Commercialization Costs. Takeda shall use Commercially Reasonable Efforts to Commercialize Products in the Field in the Territory in accordance with the Commercialization Plan and the terms of this Agreement, subject to Amylin’s co-Commercialization of Products pursuant to Section 5.3, and the terms of any Co-Commercialization Agreement. […] 5.3 Amylin Co-Commercialization Option. Subject to the terms and conditions contained in this Section 5.3, Takeda hereby grants to Amylin an option to co-Commercialize with Takeda the first two (2) Products containing different clinically active ingredients that have received Regulatory Approval by the FDA in the United States, and any additional Products that receive Regulatory Approval by the FDA, which contain the identical clinically active ingredient(s) as either of the first two (2) Products (the “Co-Commercialization Option”). Copyright © 2010 Deloitte Recap LLC. All rights reserved. 32
34.
Co-Commercialization Option Deciphered §
Takeda has sole WW commercialization rights § Amylin can choose to co-commercialize the first 2 products approved by the FDA § Amylin must exercise option within CON of Ph. III trial unblinding and the co-commercialization will last for CON § Amylin is responsible for costs of co-commercialization, to be reimbursed by Takeda at CON% of internal detailing costs Copyright © 2010 Deloitte Recap LLC. All rights reserved. 33
35.
Avoid § Not including
the “Musts” § Poorly defined “Icing” § Your lawyer should be looking out for everything else Copyright © 2010 Deloitte Recap LLC. All rights reserved. 34
36.
A final word
on value creation
37.
SGEN t18m Share
Price $16.00 “The 75% response rate and six Sept. 28 months plus durability easily Brentuximab exceeds expectations” Phase III trial J.P. Morgan data released $15.00 $14.00 March 11 US PTO issues patent for Brentuximab $13.00 $12.00 $11.00 “We believe SGEN is July 23 an outstanding longBrentuximab term investment Phase I trial opportunity” Oppenheimer data released $10.00 $9.00 $8.00 $7.00 $6.00 Mar-09 Apr-09 Jun-09 Dec 7 Dec 11 “We see minimal impact to the value Dacetuzumab Termination of of SGEN...use any potential weakness as Phase I trial Genentech deal a long-term buying opportunity” data releasedJ.P. Morgan for Dacetuzumab Dec. 14 “We maintain that SGEN’s unique Deal with pipeline and technology depth will Millenium is [outperform the market]” announced Blair & Company William Jul-09 Sep-09 Nov-09 Dec-09 Feb-10 Apr-10 May-10 Jul-10 Sep-10 Copyright © 2010 Deloitte Recap LLC. All rights reserved. 36
38.
AMLN t18m Share
Price $26.00 March 15 “We expect a Class 2 designation, FDA sends complete A 180 day review period, and a response letter: REMS Q4/10 approval…Target: $11” Canaccord Adams and labeling issues $24.00 Sept. 10 Stock trend continues to be dominated by Byetta vs Victoza $22.00 $20.00 $18.00 $16.00 “The Lantus scare will not continue to help Amylin, June 26 and Byettathat slip due to Reports will a lack of differentiation” Sanofi’s Lantus Jan 26 Novo Nordisk launches Victoza (Byetta competitor) J.P. Morgan causes cancer $14.00 June 9 “Victoza has effectively been taking No significant press share from Byetta” releases in nearly J.P. Morgan three months $12.00 $10.00 $8.00 $6.00 Mar-09 Apr-09 Jun-09 October 30 October 30 label not Takeda Byetta label “Updated Byetta Deal with likely expansion to impact sales, approved as stand-alone but removes overhang” announced, overshadowed Morgan Stanley med for Type II Diabetes by Byetta label expansion Jul-09 Sep-09 Nov-09 Dec-09 Feb-10 Apr-10 May-10 Jul-10 Sep-10 Copyright © 2010 Deloitte Recap LLC. All rights reserved. 37
39.
Why Your Big
Deal is No Big Deal § Analysts still make noise § Broader market confidence matters § If it’s not your flagship product, no one cares (yet…) § Biotech stock prices still levered on binary events § Investors require smaller companies to “prove it” § You’re less attractive for M&A § Value is always realized through liquidity events Copyright © 2010 Deloitte Recap LLC. All rights reserved. 38
40.
About Recap Originally founded
as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area. In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC. Recap IQ Series by Deloitte is a trademark of Deloitte Recap LLC.As used in this document, "Recap" means Deloitte Recap LLC and "Deloitte" means Deloitte LLP and its subsidiaries. Please see www.deloitte.com/us/about for a detailed description of Deloitte LLP and its subsidiaries. Copyright © 2010 Deloitte Recap LLC. All rights reserved.
Télécharger maintenant